Clearstead Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Clearstead Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.1K	Buy	1,032 +32	+3%	+$704	﹤0.01%	1714
2026 Q1	$22.3K	Sell	1,000 -17	-2%	-$406	﹤0.01%	1434
2025 Q4	$27.2K	Sell	1,017 -257	-20%	-$6.14K	﹤0.01%	1618
2025 Q3	$27.2K	Buy	1,274 +271	+27%	+$6.41K	﹤0.01%	1504
2025 Q2	$21.6K	Buy	1,003 +3	+0.3%	+$56	﹤0.01%	1588
2025 Q1	$16.6K	Hold	1,000	–	–	﹤0.01%	1473
2024 Q4	$18.4K	Hold	1,000	–	–	﹤0.01%	1415
2024 Q3	$15.4K	Hold	1,000	–	–	﹤0.01%	1494
2024 Q2	$16.3K	Hold	1,000	–	–	﹤0.01%	1436
2024 Q1	$15.2K	Hold	1,000	–	–	﹤0.01%	989
2023 Q4	$31.3K	Hold	1,000	–	–	﹤0.01%	857
2023 Q3	$20.8K	Hold	1,000	–	–	﹤0.01%	885
2023 Q2	$23.9K	Hold	1,000	–	–	﹤0.01%	871
2023 Q1	$18.8K	Hold	1,000	–	–	﹤0.01%	862
2022 Q4	$15.9K	Hold	1,000	–	–	﹤0.01%	836
2022 Q3	$16K	Hold	1,000	–	–	﹤0.01%	805
2022 Q2	$14K	Hold	1,000	–	–	﹤0.01%	864
2022 Q1	$24K	Hold	1,000	–	–	﹤0.01%	820
2021 Q4	$23K	Sell	1,000 -508	-34%	-$10.2K	﹤0.01%	790
2021 Q3	$25K	Hold	1,508	–	–	﹤0.01%	739
2021 Q2	$37K	Hold	1,508	–	–	﹤0.01%	601
2021 Q1	$39K	Hold	1,508	–	–	﹤0.01%	579
2020 Q4	$81K	Hold	1,508	–	–	0.01%	448
2020 Q3	$62K	Buy	1,508 +1,008	+202%	+$43.5K	0.01%	435
2020 Q2	$24K	Hold	500	–	–	﹤0.01%	509
2020 Q1	$21K	Buy	+500	New	+$20.6K	﹤0.01%	498

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Clearstead Advisors's ACAD Position: Q2 2026 in Review

Clearstead Advisors increased its Acadia Pharmaceuticals (ACAD) stake by 3.2% in Q2 2026, buying an estimated $704 and bringing the position to 1,032 shares worth $26.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1714.

Clearstead Advisors first reported a position in ACAD in Q1 2020 and has held it in 26 quarters since. The position peaked at $81K in Q4 2020. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Clearstead Advisors held 1,032 shares of Acadia Pharmaceuticals worth $26.1K as of Q2 2026.
Clearstead Advisors bought 32 Acadia Pharmaceuticals shares in Q2 2026, an estimated $704.
Acadia Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1714 holding.
Clearstead Advisors first reported a position in Acadia Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
Clearstead Advisors's Acadia Pharmaceuticals position peaked at $81K in Q4 2020.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.